***Background.*** The experience with cidofovir in pediatric SOT is limited. The study aimed to assess the impact of cidofovir use on the renal function.

***Methods.*** Summary statistics were presented for demographics and outcomes, Wilcoxon signed-rank tests to compare changes in renal function and Wilcoxon rank-sum tests to test association with potential confounding factors.

***Results.*** We included 25 patients (mean age 4.2years; SD 4.6): liver-small bowel (15), small bowel (4), liver (3) and kidney (3) transplant recipients. Viral infections: adenovirus (20), BKv (2), HHV6 (1), and EBV (1). 24% of patients while on cidofovir compared with 4% at baseline (p = 0.03) were on renal replacement therapy (RRT). For patients not on RRT, there was no difference: 1) in the median creatinine clearance between baseline and one month after (p = 0.32) or end of cidofovir treatment (p = 0.23); 2) in the creatinine from baseline to end of cidofovir therapy (p = 0.2); there was marginal decrease in the median creatinine from baseline to one month post-cidofovir treatment (p = 0.06). Less patients had proteinuria (72.2% vs 27.8%;p = 0.02) and hematuria (22.2% vs 0%) at the end than at the beginning of cidofovir treatment. No evidences of associations were found between changes in creatinine clearance (by univariate analysis) with: exposure to vancomycin (p = 0.44), amikacin (p = 0.13), dopamine (p = 0.66), epinephrine (p = 0.99), norepinephrine (p = 0.48), intravenous contrast (p = 0.41) and surgery (p = 0.59).

***Conclusion.*** Cidofovir was mainly used to treat adenovirus infections. In our study, cidofovir did not have nephrotoxic effects during the treatment and 1 month after treatment in pediatric transplant recipients, although they required RRT while on cidofovir because of fluid overload.
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